TriSalus Life Sciences, Inc. (NASDAQ: TLSI), a medical technology company specializing in drug delivery technologies and immune-oncology therapeutics for liver and pancreatic cancer, has announced the publication of pre-clinical data demonstrating improved delivery of Embospheres® to liver tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System. This breakthrough has significant implications for the company's competitive position and market penetration in the medical device and biotech sectors.



The pre-clinical data, published in the Journal of Vascular and Interventional Radiology, shows that the PEDD method enhances the therapeutic delivery of glass microspheres to solid tumors, which could significantly impact the potential market penetration of TriSalus' PEDD technology. The TriNav infusion system, which uses this innovative method, allows for more efficient and targeted delivery of therapeutic agents to liver tumors. This improved delivery could lead to better treatment outcomes for patients with liver cancer and metastases, making the TriNav infusion system an attractive option for healthcare providers and institutions.

The strategic partnership with Geo-Med, LLC, announced by TriSalus, further supports the potential market penetration of the TriNav infusion system. This partnership aims to expand access to the TriNav infusion system for U.S. veterans with liver cancer, indicating that the technology is gaining traction in the market.

Moreover, the launch of the TriNav® LV Infusion System and TriGuide™ Guiding Catheters expands TriSalus' portfolio of PEDD devices, providing more options for healthcare providers to treat liver tumors effectively. This expansion could lead to increased adoption of TriSalus' PEDD technology in the market, as it offers a comprehensive suite of solutions for liver cancer treatment.

In conclusion, the pre-clinical data, strategic partnerships, and product launches indicate that TriSalus' PEDD technology has the potential to penetrate the market significantly, as it offers improved treatment outcomes and a comprehensive suite of solutions for liver cancer treatment. This development strengthens TriSalus' competitive position in the medical device and biotech sectors, making it an attractive investment opportunity for those seeking exposure to innovative drug delivery technologies in the healthcare sector.